ArticleBMJ public health2026
'Why should I start medication when I am not feeling sick?' A qualitative study of refusal, initiation, completion and discontinuation of tuberculosis preventive treatment among people living with HIV in sub-Saharan Africa.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Introduction: Tuberculosis (TB) preventive treatment (TPT) is effective in preventing TB among people living with HIV (PLHIV). Patient experiences and preferences contribute to optimising the delivery cascade for TPT among PLHIV. We describe patient-level reasons for initiation, completion, refusal and discontinuation of 3HP (high-dose rifapentine (RPT) 900 mg plus isoniazid (INH) 900 mg weekly for 3 months) and INH in Ethiopia, South Africa and Zimbabwe. Methods: We conducted a total of 141 45-60 min in-depth interviews (IDIs) with adult PLHIV in Ethiopia (n=45), South Africa (n=45) Zimbabwe (n=51) between March and June 2022. Participants were attending routine HIV care in nine healthcare facilities and interviewed using a study-designed interview guide. The guide explored three categories: TB and TPT knowledge, reasons for TPT initiation and experiences of taking TPT and antiretroviral therapy (ART). Recordings were transcribed verbatim, translated and thematically analysed on MAXQDA using an abductive coding scheme incorporating the information-motivation-behavioural (IMB) skills model to understand reasons behind TPT uptake patterns. Results: Of the 141 participants, 28 were still on TPT, 66 completed, 22 discontinued and 25 refused to initiate TPT. The majority were female (88%, 124/141), with an average of 36 years. IMB constructs were reflected in participants' TPT uptake patterns, with illustrative quotes highlighting key patterns across the dataset. In relation to information, participants demonstrated knowledge of TPT and its benefits; however, there was confusion about the role of TPT in the absence of TB disease. Prior TB experiences, social support and engagements with healthcare workers were motivations for uptake. The main behaviours found included adoption of adherence strategies and use of medication reminders. Side effects, fears of pill burden and contraindications had negative outcomes for TPT uptake and completion. Conclusions: The findings underscore the need to enhance the understanding of TPT through targeted interventions at clinic and community levels. Strengthening these efforts may improve TPT uptake and completion rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.